This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk05: tender offer to acquire Stratasys following the offer's expiration on July 31st, 2023. Nano also announced that it withdraw its director nominees for the Stratasys board at our annual general meeting of shareholders that took place yesterday. We thank our shareholders for their feedback and are pleased that our shareholders voted to re-elect each of Stratasys director nominees to continue supporting our efforts to execute on our strategy to deliver significant long-term growth and maximize value for our company and our shareholders. That said, The purpose of this call is to discuss our financial and operating results, and we ask that you keep your questions to that. Turning to the results, our strong second quarter results represent another consecutive quarter of solid performance marked by record recurring revenues from consumable sales and customer service revenues. These results demonstrate the success of our winning strategy, which includes our leadership position in 5 polymer additive manufacturing technologies, resilient business model, and strong financial profile. The work we've done to execute our strategy has put us on track to achieve our medium-term forecast as a standalone company of generating more than $1 billion in organic revenue in 2026, without significant M&A activity, in addition to making substantial improvements in profitability over the coming years. We believe that this expectation will be further bolstered by the addition of desktop metal. Together, we believe we are positioned to achieve outsized growth and create long-term shareholder value for years to come. We accomplish these results against the ongoing challenging macro backdrop that continues to be marked by slower growth and higher interest rates as the global economy works to overcome recent periods of high inflation. Despite the macro situation, I'm pleased that customer demand and our engagement with both our installed base and new customers is stronger than ever. Our results show that our customers recognize that we offer a unique combination of industry-leading polymer technologies, the broadest set of polymer materials, a unified software platform across the portfolio, unmatched go-to-market capabilities, and excellent customer service. But we are not stopping there. Our suite of technology offerings continues to expand as we broaden our customer reach and gain share, particularly in manufacturing applications. Our resilient and recurring business model delivered adjusted gross margin this quarter that were 90 basis points higher compared to the year-ago period and 120 basis points higher sequentially. Additionally, we improved OPEC spending as a percentage of revenue relative to the corresponding period last year. As a result of our efforts, and despite the headwinds faced I'm proud that we delivered positive adjusted earnings per share for the eighth consecutive quarter. Our vision for the future of additive manufacturing and our leadership position in this industry is more robust than ever. We ended the quarter with a strong balance sheet of over $200 million in cash and equivalents and no debt. even after the closing of Covestro assets acquisition. This continues to support our growth through organic investments and accretive acquisition opportunities, including early stage but highly compelling technology-driven businesses, which we believe will further improve results as we leverage our infrastructure and experience to strengthen operations. Now, let me touch on some of the milestones we achieved in the second quarter of 2023. In dental, the second quarter was the first quarter of availability for our entry-level J3 dentajet printer, as well as our disruptive digital denture solution, TrueDent. And we are off to a fast start. The new J3 DentaJet for mixed trade of various dental parts has seen strong U.S. and EMEA customer response. And as noted last quarter, TrueDent is the only FDA-cleared, full-color, monolithic, 3D-printed denture solution on the market. We have already sold a number of these systems. including to Posca Brothers, Artisan, and Express, three U.S. dental labs. Notably, the top five producers of dentures in the U.S. are either committed or deep within their evaluation process and likely to buy. We are also still on track for European availability next year and have already engaged with the top ten European denture producers. The feedback has been excellent. and we look forward to updating you next year when we receive CE approval and can begin commercialization. As a reminder, Denture is an over $5 billion addressable market with only 5% coming from additive manufacturing today. Our leading technology and offerings are designed to further penetrate that impressive time and will drive sales in a large and growing segment. On the industrial side, we had a strong quarter for the Stratasys F900, our largest format FDM system, designed for high-end parts and tooling applications. Most of the units were sold into aerospace, automotive, and defense verticals. For production part manufacturing, F900 purchases included existing customers such as BMW and Lucid for factory production tooling, the U.S. Air Force, and new customers including Comac, the commercial aircraft corporation of China, which purchased two units to begin their path toward FDM flight parts. After a successful beta program featuring customers in the U.S. and EMEA, we launched our PA-12 material for SAF. PA-12 is a highly versatile polymer and the most requested material in powder bed fusion. Combining PA-12 with the consistency of SAF technology opens up a world of high-volume applications that require advanced level of dimensional accuracy with a lower cost per part. Along with our channel partners, TCL Hoffman in Australia, we announced a partnership with walk-in show Andretti United Racing Team to encode the new AM hub with a new Stratasys 42450MC 3D printer. Their second such printer. The team uses 3D printing to prototype and produce parts faster and more accurately. that perform exceptionally well in challenging racing environments. We are proud of the continued progress and contributions our technologies are making in the highly demanding arena of automotive racing all over the world. Also in automotive, we announced that Peugeot has integrated our innovative 3D fashion technology into the interior of its new inception concept. achieving a level of resolution not possible using traditional embellishment methods. The car incorporates a revolutionary interior design and features advanced materials produced exclusively using Stratasys J850 textile 3D printers. Turning to medical. In the second quarter, we forge a joint development and commercialization agreement with Cold Plant Biotechnologies to transform healthcare with industrial-scale bioprinting of tissues and organs. The initial focus of the relationship will be around development of bioprinting solution for cold plants regenerative breast implants and represents a $2.6 billion opportunity Further, the combination of our P3 technology-based bioprinter with their Rh collagen-based bio-inks is ideal for future innovation and production of additional human tissues and organs. Both companies have agreed to cross-promote their respective bioprinting products, and we look forward to collaborating toward a successful commercialization. of ColdPlant's novel regenerative breast implants and beyond. Just last week, we celebrated the FDA clearance of Axial3D's automated cloud-based medical segmentation software. As a reminder, we invested in Axial3D, a cloud-based, AI-driven 3D printing platform that enables easy segmentations of CT and MRI scans for anatomic models. Healthcare providers and medical device company use a cloud service to quickly go from scan to 3D printed anatomic models without large upfront capital expenses. Therefore, the ability and scalability can help accelerate adoption of 3D printed medical models across thousands of hospitals. This is an important milestone, as the ability to help global medical device manufacturers deliver patient-specific surgical solutions holds the promise of multi-million dollar agreements with them. And the key is speed and efficiency. FDA clearance is expected to provide a major boost towards scaling up production processes. Turning to slide 9. Early in the quarter, we announced the revenue-generating premium version of our flagship GrabCut print software. GrabCut Print Pro is designed to improve efficiency of the print preparation process for our FDM and SAF customers, and will be extended to our other 3D printing technologies in the months ahead. We are now automatically attaching it to new FDM and SAF system purchases. We generate a recurring revenue stream. Rabkat Print Pro also includes capabilities from our Riven acquisition integrated as accuracy center, which reduces the number of prints in order to achieve even more accurate parts. You may recall that last year, We acquired Riven, an AI software company, which helps customers quickly create consistently accurate and used production parts at scale. The response is encouraging, with several initial purchases during the quarter, including Boeing, Over 75 companies are trialing GrabCut Print Pro and we have plans to roll out an additional revenue generating software solution later this year. As we continue to focus on adding value for customers while increasing recurring revenue through significant software enhancements. During the second quarter, we closed the acquisition of Covestro's additive manufacturing materials business. which expands our differentiated 3D printed materials offering in stereolithography, DLP, and powders to address more manufacturing industry applications. We welcome the R&D facilities, global development, and sales teams around the world. A portfolio of 60 materials for additive manufacturing and their extensive IP portfolio to our leading suite of consumables offerings. The addition of Covestro yielded immediate results and contributed to another record quarter of consumable revenues. We expect to introduce new materials resulting from the acquisition later this year. Our technological innovations Best-in-class sales channels and key partnerships are contributing to our effort to build on our meaningful foundations for growth that will drive our industry leadership for long term. I will now turn the call over to our CFO, Eitan Zamir, to share the financial results and updates on our outlook for the rest of 2023. Eitan?
spk04: Thank you, Yoav, and good morning, everyone. As Yoav mentioned, we achieved another quarter of solid results against a persistently challenging backdrop in our customers' capital spending cycles. We are particularly proud of how we improved both growth and operating margin. We chose the progress we continue to make in driving efficiencies across the platform. Overall, our results reflect the resilience our diversified offerings provide, the signs of acceleration in sales of manufacturing-oriented systems, and the continued strong utilization of our systems by our customers. Now, let me dive deeper into the numbers. For the second quarter, consolidated revenue of $159.8 million was up 2% adjusted for constant currency and Makeabot relative to Q2 2022. In aggregate, revenue was down 4.1% and down 3.7% at constant currency compared to Q2 2022. OEM revenue, which excludes both Makeabot and FDM, was up 3.3% at constant currency from prior year period. Product revenue in the second quarter declined by 5.7% to $109.1 million compared to the same period last year and was up 1.5% excluding make-a-bought and on a constant currency basis. Within product revenue, system revenue declined by 17.9% to $48.3 million compared to $58.9 million in the same period last year. Excluding MakerBot and at constant currency, system revenue was down 8.1%. On a sequential basis, system revenues grew 19.4%, indicative of the improving conditions we see in the market and the continued strong levels of engagement we see with our customers. Specifically, we saw strength in automotive, aerospace, and government for true production of end-use parts, as you have noted earlier. Consumables revenue rose by 6.9% to $60.8 million compared to the same period last year, and rose by 7.3% on a constant currency basis, and by 10.8% at constant currency excluding Makeable. This represents another record level for Stratasys. Service revenue, including SDM, was $50.7 million, essentially flat as compared to the same period last year. After backing out SDM, it was up 3.8% and up 4.1% at constant currency. And our customer service revenue was the highest ever, a further testament to the growing utilization rates of our system. Within service revenue, customer support revenue, excluding divestitures, grew 8% compared to the same period last year, and increased by 8.5% on a constant currency basis. Now turning to gross margins, GAAP gross margin was 41.5% for the quarter, compared to 40.5% for the same period last year. Non-GAAP gross margin was 48.5% for the quarter, compared to 47.6% in the same period last year. The improvement in gross margin was driven by lower freight costs and the divestiture of makeable, which helped offset lower year-over-year hardware sales. Gap operating expenses were $99.9 million compared to $90.9 million during the same period last year. The increase in gap operating expenses reflected, in large part, our one-time extraordinary costs associated with nano-dimension expired partial tender offer and withdrawn proxy contest, 3D systems proposals, and the combination we announced with Desktop Metal. Non-GAAP operating expenses were $72.5 million compared to $77.4 million during the same period last year. This decrease reflects the divestiture of MakerBot and tight OPEX management, which more than offset the inclusion of Covestro in the quota. Non-GAAP operating expenses were 45.4% of revenue for the quarter, compared to 46.4% for the same period last year, as we continue to focus on operational efficiency improvement. We continue to manage our costs, delivering relatively low OPEX to improve non-GAAP operating profitability, despite the lower revenue reflecting the scalability of our model. Regarding our consolidated earnings, gap operating loss for the quarter was $33.7 million compared to a loss of $23.5 million for the same period last year, reflecting the one-time extraordinary cost described earlier. Non-gap operating income for the quarter was $5 million compared to $1.9 million for the same period last year. The change is attributable to a 110 basis point improvement in non-GAAP OPEX as a percentage of revenue, which more than offset the decline in revenues. GAAP net loss for the quarter was $38.6 million, or $0.56 per diluted share, compared to a net loss of $24.4 million, or $0.37 per diluted share, for the same period last year. The increase in GAAP net loss was due in large part to the costs associated with Nano Dimensions' expired partial tender offer and withdrawn proxy contest, 3D Systems' proposals, and the combination we announced with Desktop Metal, which are excluded from non-GAAP. Non-GAAP net income for the quarter was $2.5 million or $0.04 per diluted share, compared to net income of $1.2 million or $0.02 per diluted share in the same period last year. We're proud to report that this was our eighth consecutive quarter of delivering positive net income on an adjusted basis. Adjusted EBITDA was $10.6 million for the quarter, compared to 7.4 million in the same period last year, which reflects a 220 basis point improvement year over year on a percentage of revenue basis. As you see on slide 16, we used 23.2 million of cash in our operations during the second quarter, compared to the use of 22.8 million of cash in operations for the same quarter last year. The use of cash was primarily driven by the timing of annual incentive payments, increases in accounts receivable, and costs associated to acquisitions, proxy contests, and related professional fees. We ended the quarter with $205.4 million in cash, cash equivalents, and short-term deposits, which in part reflects the impact of closing Covestro in the quarter. Our balance sheet and cash generation remains strong. Specifically, we are well capitalized and well positioned to capture value enhancing market opportunities as they are identified, including the pending transaction with Desktop Metal. Now let me turn to our outlook for 2023 and the medium term. We are reiterating our revenue guidance of 630 million to 670 million. Due to timing, we anticipate continued sequential quarterly growth this year, with third quarter higher than second quarter, and the fourth quarter should be our largest. From a gross margin perspective, we continue to expect full year 2023 to be in the range of 48% to 49%, with improved year-over-year growth in the second half of 2023. We expect our margins to get back over 50% next year. In 2023, we expect our non-GAAP operating expenses to be in the range of approximately 290 to 300 million. We continue to expect non-GAAP operating margins to be in the range of 2.5% to 3.5% for the full year. In the medium term, we expect non-GAAP operating margins to achieve double digits as our growth plan unfolds. We anticipate a GAAP net loss of $115 to $96 million, or $1.66 to $1.39 per diluted share. a non-GAAP net income of $9 to $17 million, or $0.12 to $0.24 per diluted share for the full year of 2023. Our GAAP results and thus our outlook includes the one-time extraordinary costs associated with the proxy contest and merger-related activities. Adjusted EBITDA is expected to be in the range of 35 million to 50 million for the year. Capital expenditures are expected to range between 20 to 25 million for the year. Despite the near-term challenges that persist due to macroeconomic conditions and the corresponding capital investment down cycle by our customers, we are reiterating our medium-term targets discussed on our last call. Those targets are for non-GAAP growth margins, about 50%, and positive free cash flow starting next year. By 2026, we continue to expect our revenue from organic growth to surpass $1 billion, with adjusted EBITDA margin surpassing 15%, driven by our innovative growth engines as we penetrate further into manufacturing and healthcare applications. Please note these figures are for Stratasys standalone and do not include anticipated benefits from our pending combination with Desktop Meta. In summary, we generated strong financial results against the continued challenging backdrop and we remain encouraged by the level of engagement with our customers and confident in our long-term growth and profitability potential. With that, let me turn the call back over to Yoav for closing remarks. Yoav? Thank you, Eitan.
spk05: Our customers' appreciation and adoption of 3D printing continues to grow as we are an increasingly essential part of their efforts to bring more agility, flexibility, and profitability to their global manufacturing operations. I also want to acknowledge and thank the employees of Stratasys. They have furthered the execution of our strategy with excellence, helping to make Stratasys the healthiest, and the strongest growing business in our industry. We look forward to the future and we remain unwaveringly committed to delivering on our plans as we seek to generate long-term value for our shareholders. With that, let's open it up for questions. Operator?
spk03: Thank you. Before we open the floor for questions, our Chief Executive Officer, Yoav Zeiss, would like to make a brief statement.
spk05: Thank you, Operator. And good morning, everyone, to join us. Before we begin Q&A, as an update on 3D, I want to be very clear. We have been meeting with and exchanging significant information with 3D as part of our deciding if a 3D combination can result in a superior proposal to the one we signed with Desktop Metal. We have had a number of joint meetings and exchanges of information and have more already scheduled so we can arrive at an informed decision as soon as practical. As always, there can be no certainty that a transaction will result and note that we have a signed agreement with Desktop Metal. We believe these things are best done privately and constructively. And as I said, we aren't going to be taking any question on M&A. Now let's get to our earnings, which illustrate the progress we have made. And now, operator, please open it up for questions.
spk03: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the start keys. We kindly ask participants to limit themselves to one question and one immediate follow-up. Please hold while we poll for questions. Our first question comes from Greg Palm with Craig Hallam. Please go ahead.
spk07: Yeah, hey, thanks, everyone. Thanks for taking the questions. I guess just starting off with maybe the quarter and the outlook, I'm just curious, just in terms of visibility levels, what's changed? What's the same? Anything better? Anything worse than a few months ago? And just maybe relative to some of the peers or others that play in the capital equipment space, a little bit better results. I'm just curious, you know, in terms of the outperformance, where it's coming from.
spk05: Thank you, Greg, and good morning. So, no doubt that the entire industry is operating in a challenging environment because we are in a deflection point and we are moving to manufacturing, but manufacturing players are facing also economic challenges and put kind of a break on their capex. So all of us are operating in a challenging environment. However, the nice thing in Stratus is that we are very diversified and we are providing a full solution across the product development life cycle, but also across verticals, which allow us to be quite diversified. And on top of it, we have very clear set of growth engines. The first thing that happened over the last three years that we almost tripled our addressable market. Then we also made some acquisitions that, you know, suddenly we see them in the market and they are contributing both revenues and profitability. So when you put this together, the Covestro and the strong material offering that we have and the growth in consumable and recurring revenue plus new offering in dental plus new launches that we will have this year and put everything together into one strong infrastructure in the market of go to market and an amazing network of partners that feed us with information about the market Two very strong systems. We have good visibility for H2. We have good visibility and we see the light at the end of the tunnel. It's starting in the U.S. It's a bit better. You can see it also on our hardware sale that significant improvement from Q1, which above 19%, 19.4% improvement from Q1. So when you put everything together, the growth engine, the acquisition, the go-to market, and the infrastructure that we have, we are such a structured company, we have good visibility for H2. And that's why we kept our guidance.
spk07: Okay, great. And just in terms of guidance, next year, in one of the M&A slide decks, you put out some base case and downside case scenarios for Stratasys as a standalone business. And I just wanted to maybe dig into that a little bit further because the base case, you know, 20 plus percent growth relative to this year at the midpoint and even in a downside case, pretty strong double digit growth. So, I know that's not guidance per se, but what gives you maybe the visibility next year that you think you can re-accelerate growth to that extent?
spk04: Thanks, Greg, for the question. It's Eitan. So, to start, you related to the two models. Keep in mind that some of the drivers that you have related to, are the same answer for this question, right? The acquisition of Covestro, that's something that did not impact our revenue at the beginning of the year. In 2024, it's going to hit full year, and we believe that we can grow that business. When you think about the acquisition of Origin, ZAR, which is SAF, and RPS, those businesses continue to grow and will have more and more impact as we go to manufacturing. and we continue our journey. The denture that you have mentioned, all these growth driver and keep in mind that the beginning of 2023 and even now is in unstable macro environment. So when you take all these together, we have the infrastructure, the business, the go-to market that can enable us to grow significantly year over year in normal macroeconomic environment. Add to that the software, which is another growth engine for us, and you get a complete picture of many growth drivers that could get us there.
spk07: Okay, thanks for the help. I'll hop back in the queue.
spk03: Thank you. Our next question comes from Shannon Cross with Credit Suisse. Please go ahead.
spk06: Thank you very much. I also wanted to talk a bit about what you saw during the quarter and guidance. You know, we just got off the 3D Systems call where they talked about pushed out orders, you know, that they saw during the quarter, which then closed in July, but they're seeing further push out. So I'm just wondering maybe if you can talk about linearity during the quarter. You know, are you seeing delays in terms of order rates, you know, And maybe, I don't know if you can just sort of contrast it to, I don't know if it's different product sets that 3D system has versus yours, but again, it's kind of a tale of two cities in terms of the commentary during the calls. And then I have a follow-up. Thank you.
spk05: Hey, Shannon. Good morning. Thank you for your question. So we definitely see longer sales cycles, but we don't see significant changes push of orders going forward. And I guess it's also related to our diversification geographically across different customers, but also the improvement in the U.S. So the U.S. is still, the overall economy is still shrinking because you can see it in the purchasing managers index. But it's less severe than it was in the past, in the last three, four quarters. So kind of the wave of economic challenge moved to the other side of the ocean. And we are US-based, 60% of our revenues. So we do see much better customer engagement, very strong, especially in the US. So the demand is there with a longer sales cycle, but we specifically didn't see a push in order to the next quarter.
spk06: Okay, thank you. And I'll see if you can answer this. We'll try it. You're undergoing, you know, initial integration work, looking at desktop metal. I'm just curious, as you're doing that, has anything changed in terms of what you saw going into the acquisition? Are you, you know, are there, like, what areas are you thinking are most complementary to Just kind of curious as to how that's going.
spk05: So we don't see any change. And we still believe in what we announced and published about the complementary of those two businesses. So desktop metal are bringing the best metal solution that if there will be a metal solution in mass production it will be desktop metal for sure and they bring amazing position in dental they are the leader in digital casting which is large format part of metal and they are super innovative and when you combine this with Stratasys polymer leading position with Stratasys go to market which is the best in the industry and with Stratasys infrastructure we see great complement parity between the two companies, and that's why we signed the agreement.
spk06: Thank you so much. Thank you.
spk03: Thank you. Our next question comes from Brian Drab with William Blair. Please go ahead.
spk02: Hi. Thanks for taking my question. I just wanted to clarify on Covestro. just how much that contributes to growth and how you think about that with respect to organic revenue growth. Because this company, the deal was closed on April 5th, and so you get a full quarter, then the second quarter of investor revenue, which is about three points of growth. I'm just wondering, how are you thinking about this, you know, roughly three points of growth with respect to, which I think you said today, 2% organic revenue growth for the company for the quarter. Is that in there?
spk04: Hi, Brian. So first to relate to your question about Covestro, you're right. The deal closed at the beginning of April and contributed $4.6 million for the quarter. We believe that business will grow. already in 2023 and anticipated further growth in 2024. That business complement our other businesses. Our go-to-market can leverage that business. So we see a significant growth and good business from Covestro. I will add to that that our consumable business and keep in mind that Covestro is entirely consumable, grew even without Covestro when you compare year over year, which I believe that was part of your question. So our business grew further with Covestro but also without Covestro.
spk02: And you made the statement 2% organic revenue growth excluding FX and MakerBot, and I didn't If I exclude Covestro as organic, then down 1%. Is that fair? I mean, that should be an acquisition revenue, right? I'm just trying to clarify. I'm just a little confused.
spk04: Yeah, so I believe we provided both. So we provided the Covestro revenue in order for you to be able to model. Okay. So you have the Makeabot, which is much more significant than that was divested in August 2022. And I believe we provide, and that's why I mentioned the growth in the consumable with and without Covestro. But to your question, the 2% includes Covestro.
spk02: Oh, I may have just missed that. You did that both ways. Okay. And Covestro should help margin somewhat, right? That you're kind of cutting out the middleman and not having to pay the markup on these many consumables that you sourced from them in the past?
spk04: Correct. Covestro is a healthy business as far as it's concerned with the profitability. Yeah.
spk02: Great. Okay. Thanks for taking my question.
spk03: Thank you. Our next question comes from Troy Jensen with Lake Street Capital Markets. Please go ahead.
spk01: Hey, first off, gentlemen, congrats on really nice results here.
spk04: Thank you, Troy.
spk01: Hey, so maybe for you, dental I know is a big focus for you guys. I guess to me I think about two different kind of big applications. So there's PolyJet for dentures and there's SLA for more like aligners. Which one do you think is kind of like better for you guys or the near-term opportunity or when you talk about the dental market, is it one more than the other?
spk05: Good morning. Maybe I'll take a step back and I'll start with our dental offering. We completely replenished our dental offering over the last three years. And we today have the broadest technological offering in dental because we are offering PolyJet, what we call DentalJet, and also J3 DentalJet and J5. And those are by far the leading inkjet machine in dental. focusing on data with great cost per part, with versatility, with flexibility, with the ability to print different application on the same tray. That's on the PolyJet. Then we have the DLP with all the advantages of our P3 technology, which mainly it's the best surface finish in the industry in DLP. And the meaning of it that there are some applications like Splint, where you need this surface finish, where we are really leading in terms of value to the end customers. And last but not least, we have the SLA offering. And also in the future, I believe also the SAF will be able to contribute to the aligners. So the SLA and the SAF can be a great solution with great cost per part for the aligners business. So this is like the overall portfolio our belief is that in the long term the winners will be the PolyJet and the DLP also in aligners by the way although we are investing and we have other solutions for aligners we believe that that would be the solution and that's this is where we are investing and in the short term no doubt that it's those two technologies starting with the dentures application, which is unique to Stratasys. It's IP protected, unique to Stratasys. No one else in the world can print monolithic dentures in one print without the labor needed in order to glue the two to the gingiva. It's a transformation. And we will improve the material as we go, and we believe it will be a standard, the next standard in dentures, and you will see, which is a $5 billion market. only the U.S. So we are very optimistic about this. It can be much bigger than strategies as a whole. And on top of it, of course, our DLP, which we invest a lot in order to make sure that DLP is becoming really a plug and play in dental.
spk01: Awesome. Very detailed. Thank you. My follow-up, I just asked on the SAF stuff, you talked about Nylon 12 coming out here. which I agree is a bigger market than Nylon 11 for you guys and a big opportunity. But are you still in kind of limited shipments with SAF, and when do you think that's going to more contribute to bigger revenue growth?
spk05: So we made amazing improvement and progress with SAF over the last six months, mainly on two aspects of the SAF. One is the P812, which is like, by far, you know, increasing our addressable market because this is the standard, the P812. But on top of it, we, together with our software solution, and we talked about it in the script, we improved accuracy dramatically. And we keep making improvements, and we have it in SDM, and customers are coming to see. But we have... A very deliberate introduction of the machine. Everybody needs to go to our SDL to make sure that he knows how to operate it. We are highly optimistic about this machine because no one has the value that we can deliver to customers in terms of cost per pump and accuracy.
spk01: Awesome. Yoav, thank you. Good luck with all this merger stuff.
spk05: Thank you, Frank.
spk03: Thank you. There are no further questions at this time. I would like to turn the floor back over to Yoav Zeiss for closing comments.
spk05: Thank you very much, everybody that joined the call. It's a pleasure to be part of this industry and to lead it. as the most healthier and strongest company in the industry with the eighth consecutive quarter of profitability. And I want to thank our teams for making it happen. And thank you for joining us, and I'm looking forward to updating you again next quarter.
spk03: This concludes today's conference call. You may disconnect your lines at this time. Thank you for your participation.
Disclaimer